Adpt.O

Adaptive Biotechnologies maintains a capital structure characterized by significant leverage relative to its equity base, with total liabilities of $287.74 million against total equity of $218.79 million. The company carries $126.57 million in long-term debt, resulting in a debt-to-equity ratio of 0.58. Liquidity is assessed as medium risk, driven by a negative net cash position after subtracting total debt from cash and equivalents of $70.50 million. The firm’s market capitalization stands at $3.54 billion, implying a high valuation multiple of 12.98x EV/Revenue and 15.73x Price-to-Book, reflecting investor expectations for future growth despite current unprofitability.

Profitability metrics remain deeply negative, with a Return on Equity (ROE) of -27.19% and Return on Assets (ROA) of -11.60%. The company reported an operating loss of $57.12 million and a net loss of $59.50 million on revenues of $276.98 million. Operating cash flow was negative at -$45.99 million, while capital expenditures were minimal at $2.96 million. The negative EV/EBITDA of -62.95 underscores the current lack of earnings before interest, taxes, depreciation, and amortization. Without cohort median data for direct comparison, these figures indicate a typical pre-profitability profile for a biotechnology firm investing heavily in R&D and commercialization.

Revenue concentration and geographic exposure details are not provided in the available data. The company’s total revenue of $276.98 million represents its top-line performance, but specific segment breakdowns or regional contributions are absent from the current snapshot. Consequently, analysis of revenue diversification or geographic risk cannot be performed based on the present information.

Growth trajectory analysis is limited by the absence of historical period data. The current revenue figure of $276.98 million serves as the baseline, but without 5-year annual or 8-quarter quarterly trends, it is not possible to assess year-over-year growth rates or revenue momentum. The company’s share count remains stable at 153.78 million basic and diluted shares outstanding, suggesting no recent significant dilution events in the latest reporting period.

Risk assessment highlights medium liquidity risk and low dilution risk. A key flag notes that net cash is negative after subtracting total debt, indicating reliance on external financing or future cash flow generation to meet obligations. The low dilution risk suggests that the current capital structure is not under immediate pressure from equity issuance, although the negative operating cash flow may necessitate future capital raises. The high valuation multiples imply that the market is pricing in significant future success, which increases downside risk if clinical or commercial milestones are not met.

Recent observations include analyst estimates with a mean price target of $23.50, a median of $23.50, a high of $28.00, and a low of $20.00. The mean recommendation is 1.75, indicating a strong buy consensus, with 3 strong buys, 4 buys, and 1 hold. News events reflect internal reconciler activities for coverage closure, with no specific external news events or filing observations disclosed in the current data set.

Revenue $71.6M, +21,5% YoY; Operating income +37,0% YoY.

• ▍Revenue $71.6M, +21,5% YoY
• ▍Operating income +37,0% YoY
• ▍Operating margin -22.0%

Revenue $70.9M, +35,1% YoY; Operating income +35,1% YoY.

• ▍Revenue $70.9M, +35,1% YoY
• ▍Operating income +35,1% YoY
• ▍Net income +32,9% YoY
• ▍Free cash flow +35,6% YoY
• ▍Net margin -28.3%

Revenue $71.7M, +51,0% YoY; Operating income +62,2% YoY.

• ▍Revenue $71.7M, +51,0% YoY
• ▍Operating income +62,2% YoY
• ▍Net income +59,7% YoY
• ▍Free cash flow +65,9% YoY
• ▍Net margin -18.9%

Revenue $94.0M, +102,4% YoY; Operating income +131,5% YoY.

• ▍Revenue $94.0M, +102,4% YoY
• ▍Operating income +131,5% YoY
• ▍Net income +129,8% YoY
• ▍Free cash flow +148,6% YoY
• ▍Net margin 10.2%

Revenue $58.9M; Operating income -$25.0M.

• ▍Revenue $58.9M
• ▍Operating income -$25.0M
• ▍Net margin -43.5%

Revenue $52.4M; Operating income -$29.6M.

• ▍Revenue $52.4M
• ▍Operating income -$29.6M
• ▍Net margin -56.9%

Revenue $47.5M; Operating income -$33.8M.

• ▍Revenue $47.5M
• ▍Operating income -$33.8M
• ▍Net margin -71.0%

Revenue $46.4M; Operating income -$32.6M.

• ▍Revenue $46.4M
• ▍Operating income -$32.6M
• ▍Net margin -69.1%

Revenue $277.0M, +54,8% YoY; Operating income +64,9% YoY.

• ▍Revenue $277.0M, +54,8% YoY
• ▍Operating income +64,9% YoY
• ▍Net income +62,7% YoY
• ▍Free cash flow +69,0% YoY
• ▍Net margin -21.5%

Revenue $179.0M, +5,1% YoY; Operating income +28,4% YoY.

• ▍Revenue $179.0M, +5,1% YoY
• ▍Operating income +28,4% YoY
• ▍Net income +29,2% YoY
• ▍Free cash flow +32,7% YoY
• ▍Net margin -89.1%

Revenue $170.3M, −8,1% YoY; Operating income −13,4% YoY.

• ▍Revenue $170.3M, −8,1% YoY
• ▍Operating income −13,4% YoY
• ▍Net income −12,5% YoY
• ▍Free cash flow −9,2% YoY
• ▍Net margin -132.3%

Revenue $185.3M, +20,1% YoY; Operating income +4,2% YoY.

• ▍Revenue $185.3M, +20,1% YoY
• ▍Operating income +4,2% YoY
• ▍Net income +3,4% YoY
• ▍Free cash flow +23,2% YoY
• ▍Net margin -108.0%